1)藤原靖弘:GERD疫学ー最近の動向.日消誌114:1781-1789, 2017
2)Fujiwara Y, Arakawa T:Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 44:518-534, 2009
3)Ang TL,et al:A comparison of the clinical, demographic and psychiatric profiles among patients with erosive and non-erosive reflux disease in a multi-ethnic Asian country. World J Gastroenterology 11:3558-3561, 2005
4)Fass R:Erosive esophagitis and nonerosive reflux disease(NERD);Comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 41:131-137, 2007
5)Drossman DA:Functional gastrointestinal disorders;History, pathophysiology, clinical features, and Rome Ⅳ. Gastroenterology 150:1262-1279, 2016
6)Aziz Q, et al:Functional esophageal disorders. Gastroenterology 150:1368-1379, 2016
7)日本消化器病学会(編):胃食道逆流症(GERD)診療ガイドライン2021(改訂第3版),南江堂,2021
8)Kusano M, et al:Development and evaluation of FSSG;Frequency scale for the symptoms of GERD. J Gastroenterol 39:888-891, 2004
9)Kusano M, et al:Development and evaluation of a modified Frequency Scale for the symptoms of gastroesophageal reflux disease to distinguish functional dyspepsia from non-erosive reflux disease. J Gastroenterol Hepatol 27:1187-1191, 2012
10)星野芳雄:GERDの診断—内視鏡診断と分類.臨消内科11:1563-1568, 1996
11)Charbel S:The Role of Esophageal pH Monitoring in Symptomatic Patients on PPI Therapy. AM J Gastroenterol 100:283-289, 2005
12)Sifrim D, et al:Gastro-oesophageal reflux monitoring;Review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 53:1024-1031, 2004
13)Numans ME, et al:Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease;A meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518-527, 2004
14)Khan M, et al:Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007:CD003244, 2007
15)日本消化器病学会(編):胃食道逆流症(GERD)診療ガイドライン2015(改訂第2版),南江堂,2015
16)Sakurai Y, et al:Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 42:719-730, 2015
17)Ness-Jensen E, et al:Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 14:175-182 e1-3, 2016
18)Miwa H, et al:Randomised clinical trial;Efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33:323-332, 2011
感染の診断と治療のガイドライン2016改訂版,先端医学社,2016
20)Stefanidis D, et al:Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc 24:2647-2669, 2010